HGEN
HUMANIGEN, INC.HGEN
HGEN
Delisted
HGEN was delisted on the 25th of July, 2023.
About: Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Employees: 6
Financial journalist opinion
Negative
Reuters
5 months ago
US says former Humanigen chief scientific officer charged with insider trading
An indictment unsealed on Monday charged the former chief scientific officer of biopharmaceutical company Humanigen with engaging in an insider trading scheme involving the firm's stock, the U.S. Justice Department said.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The settlement provides for a fund of $3,000,000 to benefit class members.
Neutral
Accesswire
1 year ago
Levi & Korsinsky, LLP Notifies Shareholders of Humanigen, Inc. (HGEN) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / February 29, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Humanigen, Inc. (NASDAQ:HGEN). The settlement provides for a fund of $3,000,000 to benefit class members.
Negative
InvestorPlace
1 year ago
HGEN Stock Alert: Why Humanigen Just Filed for Ch. 11 Bankruptcy
Humanigen (OTCMKTS: HGEN ) stock is falling hard on Friday after the company filed for Chapter 11 bankruptcy protection. This bankruptcy filing comes after Humanigen failed to secure regulatory approval for its Covid-19 treatment lenzilumab.
Negative
Reuters
1 year ago
COVID-19 treatment developer Humanigen files for Chapter 11 bankruptcy
Drug developer Humanigen HGEN.PK has filed for voluntary Chapter 11 bankruptcy, according to a court filing, after struggling to get regulatory approval for its COVID-19 treatment.
Charts implemented using Lightweight Charts™